Evidence map›Paper›PMID 42625958›Full record

ArticleTherapeutic advances in hematology2026

Hypoplastic acute myeloid leukemia with aberrant lymphoid antigen expression and

Wenxia Xia, Junyan Zou, Xiaoyong Chen, Jing Luo, Chun Feng, Mao Dai, Yanhong Ding, Jihao Zhou, Peng Ke, Huijun Li and 1 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wenxia XiaInstitute of Transfusion Medicine, Shenzhen Blood Center, Shenzhen, Guangdong, China.
Junyan ZouTianjin Union Precision Diagnosis Co., Ltd, Tianjin, China.
Xiaoyong ChenDepartment of Hematology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China.
Jing LuoDepartment of Hematology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China.
Chun FengDepartment of Hematology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China.
Mao DaiWuhan Kanglu Biomedical Co., Ltd, Wuhan, China.
Yanhong DingDepartment of Hematology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China.
Jihao ZhouDepartment of Hematology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China.ORCID https://orcid.org/0000-0002-2684-192X
Peng KeDepartment of Hematology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China.
Huijun LiDepartment of Hematology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China.ORCID https://orcid.org/0009-0006-7057-7616
Junjie HouDepartment of Hematology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China.ORCID https://orcid.org/0009-0006-3463-7271

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ewing sarcoma breakpoint region 1 (

Indexed as

acute myeloid leukemiaazacitidineEWSR1::FEV fusionlymphoid antigen expressionvenetoclax

Identifiers

PMID42625958
PMCPMC13490784

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.